Meyka Pro banner
Stereotaxis, Inc.

Stereotaxis, Inc. Fundamental Analysis (AMEX: STXS)

STXS●AMEX
HealthcareMedical - Instruments & Supplies
$0.85
$0.05(5.56%)
U.S. Market opens in 15h 14m

Stereotaxis, Inc. Fundamental Analysis (AMEX: STXS)

Stereotaxis, Inc. (AMEX: STXS) shows moderate financial fundamentals with a PE ratio of -3.49, profit margin of -70.86%, and ROE of -1.16%. The company generates $0.0B in annual revenue with strong year-over-year growth of 20.28%.

Key Strengths

PEG Ratio-0.24

Areas of Concern

ROE-1.16%
Operating Margin-69.36%
Cash Position4.57%
We analyze STXS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -127.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-127.5/100

We analyze STXS's fundamental strength across five key dimensions:

Efficiency Score

Weak

STXS struggles to generate sufficient returns from assets.

ROA > 10%
-27.21%

Valuation Score

Excellent

STXS trades at attractive valuation levels.

PE < 25
-3.49
PEG Ratio < 2
-0.24

Growth Score

Excellent

STXS delivers strong and consistent growth momentum.

Revenue Growth > 5%
20.28%
EPS Growth > 10%
16.67%

Financial Health Score

Excellent

STXS maintains a strong and stable balance sheet.

Debt/Equity < 1
0.37
Current Ratio > 1
1.08

Profitability Score

Weak

STXS struggles to sustain strong margins.

ROE > 15%
-115.83%
Net Margin ≥ 15%
-70.86%
Positive Free Cash Flow
No

Key Financial Metrics

Is STXS Expensive or Cheap?

P/E Ratio

STXS trades at -3.49 times earnings. This suggests potential undervaluation.

-3.49

PEG Ratio

When adjusting for growth, STXS's PEG of -0.24 indicates potential undervaluation.

-0.24

Price to Book

The market values Stereotaxis, Inc. at 4.08 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

4.08

EV/EBITDA

Enterprise value stands at -3.85 times EBITDA. This is generally considered low.

-3.85

How Well Does STXS Make Money?

Net Profit Margin

For every $100 in sales, Stereotaxis, Inc. keeps $-70.86 as profit after all expenses.

-70.86%

Operating Margin

Core operations generate -69.36 in profit for every $100 in revenue, before interest and taxes.

-69.36%

ROE

Management delivers $-1.16 in profit for every $100 of shareholder equity.

-1.16%

ROA

Stereotaxis, Inc. generates $-27.21 in profit for every $100 in assets, demonstrating efficient asset deployment.

-27.21%

Following the Money - Real Cash Generation

Operating Cash Flow

Stereotaxis, Inc. generates limited operating cash flow of $-14.94M, signaling weaker underlying cash strength.

$-14.94M

Free Cash Flow

Stereotaxis, Inc. generates weak or negative free cash flow of $-15.15M, restricting financial flexibility.

$-15.15M

FCF Per Share

Each share generates $-0.15 in free cash annually.

$-0.15

FCF Yield

STXS converts -18.20% of its market value into free cash.

-18.20%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-3.49

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.24

vs 25 benchmark

P/B Ratio

Price to book value ratio

4.08

vs 25 benchmark

P/S Ratio

Price to sales ratio

2.70

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.37

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.08

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.16

vs 25 benchmark

ROA

Return on assets percentage

-0.27

vs 25 benchmark

ROCE

Return on capital employed

-0.43

vs 25 benchmark

How STXS Stacks Against Its Sector Peers

MetricSTXS ValueSector AveragePerformance
P/E Ratio-3.4931.30 Better (Cheaper)
ROE-115.83%487.00% Weak
Net Margin-70.86%-1832.00% (disorted) Weak
Debt/Equity0.370.10 Weak (High Leverage)
Current Ratio1.085.74 Neutral
ROA-27.21%-165.00% (disorted) Weak

STXS outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Stereotaxis, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-2.76%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-160.44%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-211.67%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ